PPD’s Reputation Ranked Best of all CROs in Global Survey
News May 02, 2013
Pharmaceutical Product Development, LLC (PPD) announced that clinical research sites globally ranked the company No. 1 for reputation among all contract research organizations (CROs) in CenterWatch’s 2013 Global Investigative Site Relationship Survey.
PPD also ranked second on investigative sites’ evaluation of their clinical trial relationships with CROs. Overall, PPD was ranked in the top three CROs on all 36 relationship attributes that the questionnaire asked of clinical research professionals at investigative sites globally.
Not only did four of every five survey respondents say PPD had an excellent or good reputation, PPD also ranked best in “being an innovator in finding ways to improve its relationships with sites and using technology to make processes more efficient, [using] data analytics to help target where sites might have a potential issue,” according to The CenterWatch Monthly, which published the survey results today. “PPD uses its analytics to improve productivity and quality across all project functions, not just monitoring.”
Clinical research professionals at 2,032 global sites completed the biennial survey, the largest CenterWatch has conducted to measure the quality of working relationships between CROs and sites conducting clinical research.
“These survey results are a real testament to the quality of the staff at PPD,” said Paul Colvin, PPD’s executive vice president, global clinical development. “We work to hire, train and retain the best team in the industry. We feel that trust, accountability, performance and results are the basis of PPD’s strong reputation within the industry and the foundation of our relationships with our biopharmaceutical clients and our investigative sites.
“Investigative sites are critical partners in clinical research,” Colvin said. “And strong site relationships are vital to our efforts to bend the cost and time curve of drug discovery and development to help our clients deliver life-changing medical therapies to the market faster, more cost effectively and with the highest possible quality.”
PPD’s best ranking for industry reputation follows its top overall CRO ranking in 2011, the last time CenterWatch conducted the global survey. PPD was rated highest in multiple categories that year, including staff professionalism, good protocol design, study initiation, being organized and prepared, and setting realistic project timelines. PPD also was rated one of Europe’s top CROs in the 2010 CenterWatch European Site Survey.
Since 1994, CenterWatch has been a global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals, ranging from top sponsors and CROs to research sites and niche providers, as well as an engaged population of patients interested in clinical research and volunteering.
Researchers have figured out precisely why one drug binds to the serotonin receptor 5-HT2BR and activates it to cause heart problems while very similar drugs do not. They've also discovered why a third drug acts like a 5-HT2BR antagonist - it blocks the receptor's activity - while the very well-known similar hallucinogenic drug LSD does not.READ MORE
Each year in the U.S., at least 23,000 people die from infections caused by antibiotic resistant bacteria. Using computer modeling, researchers are developing the means to prevent some of those deaths. One way bacteria develop resistance is by producing pumps that spit out antibiotics, before they can do any damage. The researchers teased out the details of how one antibiotic pump works.READ MORE